BioVaxys Technology (BioVaxys Technology) Total Liabilities : $1.54 Mil (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Total Liabilities?

BioVaxys Technology's Total Liabilities for the quarter that ended in Jul. 2023 was $1.54 Mil.

BioVaxys Technology's quarterly Total Liabilities declined from Jan. 2023 ($1.40 Mil) to Apr. 2023 ($1.30 Mil) but then increased from Apr. 2023 ($1.30 Mil) to Jul. 2023 ($1.54 Mil).

BioVaxys Technology's annual Total Liabilities declined from Oct. 2020 ($0.68 Mil) to Oct. 2021 ($0.26 Mil) but then increased from Oct. 2021 ($0.26 Mil) to Oct. 2022 ($1.20 Mil).

BioVaxys Technology Total Liabilities Historical Data

The historical data trend for BioVaxys Technology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Liabilities Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Total Liabilities

0.14

0.09

0.68

0.26

1.20

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Total Liabilities	Get a 7-Day Free Trial															1.31	1.20	1.40	1.30	1.54

BioVaxys Technology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioVaxys Technology's Total Liabilities for the fiscal year that ended in Oct. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.197	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.20

Total Liabilities	=	Total Assets (A: Oct. 2022 )	-	Total Equity (A: Oct. 2022 )
	=	0.633	-	-0.565
	=	1.20

BioVaxys Technology's Total Liabilities for the quarter that ended in Jul. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.542	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.54

Total Liabilities	=	Total Assets (Q: Jul. 2023 )	-	Total Equity (Q: Jul. 2023 )
	=	1.07	-	-0.472
	=	1.54

BioVaxys Technology Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.